3 days ago
Liquidia Technologies (LQDA) Receives a Buy from LifeSci Capital
In a report released today, Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $41.00.
Confident Investing Starts Here:
Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc. According to TipRanks, Jubinville, PhD has an average return of -13.5% and a 29.41% success rate on recommended stocks.
In addition to LifeSci Capital, Liquidia Technologies also received a Buy from H.C. Wainwright's Andrew Fein in a report issued on May 29. However, on May 19, Oppenheimer downgraded Liquidia Technologies (NASDAQ: LQDA) to a Sell.
